Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia
- Farhad Ravandi(corresponding author),
- Jeffrey L. Jorgensen,
- Susan M. O'Brien,
- Elias Jabbour,
- Deborah A. Thomas,
- Gautam Borthakur
- University of Texas MD Anderson Cancer Center
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewAbstract
<p>The prognostic value of minimal residual disease (MRD) assessed by multi-parameter flow cytometry (MFC) was investigated among 340 adult patients with B-cell acute lymphoblastic leukaemia (B-ALL) treated between 2004 and 2014 using regimens including the hyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine) backbone. Among them, 323 (95%) achieved complete remission (CR) and were included in this study. Median age was 52 years (range, 15-84). Median white blood cell count (WBC) was 9·35 × 10<sup>9</sup>/l (range, 0·4-658·1 ×1 0<sup>9</sup>/l). MRD by MFC was initially assessed with a sensitivity of 0·01%, using a 15-marker, 4-colour panel and subsequently a 6-colour panel on bone marrow specimens obtained at CR achievement and at approximately 3 month intervals thereafter. MRD negative status at CR was associated with improved disease-free survival (DFS) and overall survival (OS) (P = 0·004 and P = 0·03, respectively). Similarly, achieving MRD negative status at approximately 3 and 6 months was associated with improved DFS (P = 0·004 and P < 0·0001, respectively) and OS (P = 0·004 and P < 0·0001, respectively). Multivariate analysis including age, WBC at presentation, cytogenetics (standard versus high risk) and MRD status at CR, 3 and 6 months, indicated that MRD negative status at CR was an independent predictor of DFS (P < 0·05). Achievement of an MRD negative state assessed by MFC is an important predictor of DFS and OS in adult patients with ALL.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 392-400 (9 pages)Journal (Volume, Issue Number)
British Journal of Haematology (Volume 172, Issue 3)Publication milestones
- Published - 02/01/2016
Publication status
Published - 02/01/2016
ISSN
0007-1048Publication IDs
- Scopus: 84955727108
- PubMed: 26492205
- ORCID: /0000-0002-8636-1071/work/68811140
Publication metrics
Metrics
SciVal
citations
70
SciVal
FWCI
3.92
SciVal
Author count
22
SciVal
Paper percentile
97
SciVal
Top percentile
5
Fractional count
1
Fractional count
0.05
Fractional count
21
Fractional count
0.95
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Citation count
108
Mentions
1
Social media
11
Captures
96
Funding Details
FunderFunding number
NCI
P30CA016672
